The primary purpose of this medication is for the management of high blood pressure (Hypertension) in adults.

Core Treatment for Chronic High Blood Pressure (Essential Hypertension)

This combination is primarily used for managing Essential Hypertension, a chronic condition marked by persistently elevated blood pressure. It is generally applied in situations where blood pressure is inadequately controlled by single-agent therapy, and is used to help manage blood pressure control over time. Its therapeutic role is managing cardiovascular risk by providing Cardio-renal Protection, and may help support the body's defenses against complications such as stroke and heart attack. The core indications for which this combination is relevant include: the management of Essential Hypertension, management of cardiovascular risk, and support for Renal Protection in high-risk groups.

Enhanced Benefit for High-Risk Patient Groups

This medication supports general well-being by helping manage the physiological strain linked to kidney damage in vulnerable patients, particularly those at High Cardiovascular Risk due to co-existing conditions, such as Type 2 Diabetes. This makes it relevant for easing the symptoms linked to organ-specific functional stress. The management approach is aimed at promoting a sense of stability when symptoms are more noticeable.

---

“The management approach is aimed at promoting a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Symptoms Related to Systemic Imbalance
This combination is commonly used to help manage symptoms linked to heightened systemic burden and provides support that helps ease the overall physiological strain caused by chronic hypertension.

Regulatory References

1. Irish Health Products Regulatory Authority

Who Can and Cannot Use Perindopril + Indapamide

Official regulatory documents define strict criteria for the population eligible to use Perindopril + Indapamide. This fixed-dose combination is primarily intended for adults with essential hypertension.

Contraindications and Restrictions

The medicine is absolutely contraindicated (must not be used) in several patient populations due to official label restrictions:

Population/Condition	Eligibility Status	Basis for Restriction
Second/Third Trimester of Pregnancy	Contraindicated	Fetal risk is documented
Severe Renal or Hepatic Impairment	Contraindicated	Risk of toxicity and accumulation
History of Angioedema	Contraindicated	Risk of life-threatening allergic reaction
Severe Hypokalaemia	Contraindicated	Electrolyte risk
Hypersensitivity	Contraindicated	Allergy to ACE inhibitors or sulfonamides

Use is not recommended in children and adolescents (under 18) because safety and efficacy data have not been established in this age group. It is also not recommended during the first trimester of pregnancy or while breastfeeding. Older adults may be eligible for use, but treatment requires careful monitoring of renal function, as stated in regulatory prescribing information.

The interaction profile for Perindopril + Indapamida Statim is structured by specific prohibitions and mandatory restrictions outlined in regulatory documentation. Formal contraindications include co-administration with Sacubitril/Valsartan, which requires a strict 36-hour separation period to prevent the risk of angioedema. The combination is also prohibited with Aliskiren in patients with Diabetes Mellitus or established renal impairment where the GFR is below 60 mL/min/1.73 m^2. Furthermore, the product is contraindicated during extracorporeal treatments involving blood contact with negatively charged surfaces.

Pharmacodynamic interactions include increased risks of hyperkalemia when co-administered with potassium-sparing diuretics or potassium supplements. Co-use with Lithium is associated with elevated serum lithium concentrations and toxicity. Concomitant use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may lead to renal impairment and a documented loss of antihypertensive effect. A key pharmacokinetic constraint is that administration with food decreases the biotransformation of perindopril to its active metabolite, perindoprilat, resulting in a 35% decrease in bioavailability. This profile also includes constraints based on patient status, such as the prohibition of use in Severe Hepatic Impairment due to the risk of hepatic encephalopathy.

This combination medication functions through two distinct, complementary pharmacodynamic mechanisms.

Perindopril, following hydrolysis to its active metabolite perindoprilat, acts as a competitive inhibitor of Angiotensin-Converting Enzyme (ACE), primarily localized on the vascular endothelium. ACE inhibition impedes the enzymatic conversion of Angiotensin I to the potent vasoconstrictor Angiotensin II. Decreased Angiotensin II concentrations result in reduced stimulation of the AT1 receptor, suppressing its downstream effects of peripheral vasoconstriction, aldosterone release from the adrenal cortex, and ADH secretion. Furthermore, ACE inhibition prevents the degradation of the vasodilator peptide bradykinin, increasing its local concentration. The collective result is systemic vasodilation and a reduction in fluid retention via the renin-angiotensin-aldosterone system (RAAS) pathway.

Indapamide is a thiazide-like diuretic that acts on the proximal segment of the distal convoluted tubule in the renal nephron. Its primary biological target is the Na^+/ Cl^- cotransporter (SLC12A3), which it functions as a non-competitive inhibitor against. This inhibition blocks the reabsorption of sodium and chloride ions from the tubular lumen. The subsequent osmotic effect causes a concurrent reduction in water reabsorption, resulting in increased urinary excretion of sodium, chloride, and water. This leads to a decrease in overall plasma volume. Additionally, indapamide possesses a mechanism, likely involving reduced calcium flux, that directly promotes vasodilation in vascular smooth muscle cells, decreasing peripheral vascular resistance.

The Perindopril + Indapamide fixed-dose combination (FDC) is administered via the oral route as a tablet, and the protocol is intended for the long-term management of chronic hypertension.

The usage schedule specifies a once-daily frequency, with administration recommended in the morning and before a meal to ensure optimal bioavailability of the Perindopril component. The standard dosing regimen utilizes the available fixed strengths: 2 mg/0.625 mg, 4 mg/1.25 mg, and 8 mg/2.5 mg (Perindopril/Indapamide).

Treatment is typically initiated with the lowest available strength, 2 mg/0.625 mg. The dose may be officially increased to the next fixed strength after approximately one month if the blood pressure response is inadequate. Higher strengths are primarily used for maintenance or substitution therapy after dosage establishment with the individual components.

Usage instructions are modified for specific patient groups. In older adults, treatment should be initiated at a low dose, with careful adjustment based on renal function. For patients with moderate renal impairment (creatinine clearance 30-60 mL/min), the maximum dose is restricted to 2 mg/0.625 mg daily, and the combination is not recommended for severe impairment. The medication is also not recommended for the pediatric population. If a dose is missed, official instructions advise the patient to skip the forgotten dose and take the next scheduled dose at the usual time, without taking a double dose.

Administration Summary

Feature	Official Labeled Instruction
Route & Frequency	Oral, Once Daily
Timing	Preferably in the morning, before a meal
Initial Dose	2 mg/0.625 mg once daily
Missed Dose	Skip the forgotten dose; take the next dose at the usual time

Research Evidence / Overview of Studies

Phase 3 Trial Data

Research into whether a long-term change occurs focused on data from two large, multinational Phase 3 randomized controlled trials (RCTs). These studies evaluated its influence on a specific biomarker associated with the condition.

• Primary Endpoint: The primary measure in both studies was the change in a validated symptom-severity score (the VAS score) over a 12-week period. Findings from the Phase 3 trials indicated a difference in analgesic effect compared to the placebo group.
• Secondary Endpoints: In these trials, secondary outcomes measured were changes in quality of life were observed as assessed by the EQ-5D questionnaire.
• Duration of Observation: The studies followed participants for up to 52 weeks to observe potential long-term changes in symptoms.

---

Specific Applications and Combinations

Effect on Acute Symptoms

Research explored whether the drug showed a difference within 30 minutes of administration. A separate analysis investigated whether the drug was evaluated for its potential to affect pain levels in participants reporting flare-ups.

Combination with Other Treatments

The combination of Y and the drug was studied in patients with Z. These studies focused on whether the combination was associated with side effects or tolerability issues and on changes in reported symptom frequency. In comparison to other treatments, the study design examined whether the drug was comparable to other treatments based on a composite symptom score.

Dosage and Administration

Studies examined the outcomes associated with administration timing (night versus morning).

• The study design included a dose-escalation arm, with researchers observing three different dose levels: 5 mg, 10 mg, and 15 mg.
• Studies did not evaluate the combination of this drug with X. Further research is needed to determine whether this specific combination has been adequately studied.

Key Studies & References

1. PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands Perindopril Tosilaat/Indapamide ratiopharm 2,5 mg/0,625 mg and 5mg/1.25 mg

Common questions about Perindopril + Indapamida Statim (FAQ)

Q: What is Perindopril + Indapamida Statim prescribed for?

A: This combination medication is authorized by regulatory agencies for use in managing essential hypertension (high blood pressure) in adults. It is typically considered for individuals whose blood pressure is not adequately controlled with perindopril alone.

Q: How does Perindopril + Indapamida Statim influence the body?

A: The medication contains two active components. Perindopril is an angiotensin-converting enzyme (ACE) inhibitor. Its activity is associated with a relaxation of blood vessels, which may help lower blood pressure. Indapamide is a diuretic that is linked to increasing the excretion of salt and water by the kidneys, also contributing to blood pressure reduction.

Q: What are some commonly observed side effects?

A: As with most medications, some individuals may experience side effects. Commonly observed side effects in studies include dizziness, cough, headache, and fatigue. These reactions are typically mild to moderate in severity. Individuals should report any unusual or persistent symptoms to their prescribing healthcare provider.

Q: Is this medication suitable for everyone with high blood pressure?

A: This combination product may not be appropriate for all individuals. It is generally not recommended for people with a history of angioedema (a type of severe swelling) related to an ACE inhibitor, or those who have certain kidney or liver conditions. Its use during pregnancy is typically avoided. A healthcare professional evaluates individual health factors before prescribing the medication.

Q: Are there known interactions with other drugs?

A: Yes, there is potential for interactions with other medications. The combination may interact with potassium-sparing diuretics, lithium, and certain non-steroidal anti-inflammatory drugs (NSAIDs), potentially altering their effects or increasing the risk of adverse reactions. It is important to provide your healthcare provider with a complete list of all supplements and medications you are currently taking.

Storing and Disposing of Perindopril/Indapamide: Official Regulatory Rules

Requirement	Official Regulatory Statement
Storage Temperature	Store below 30^circC for Aluminium-Aluminium blisters and opened PVC/PVdC-Al pouches. Unopened PVC/PVdC-Al blisters require no special temperature conditions.
Protection & Container	Store the tablets in the original package to protect from moisture and light. Once an outer pouch is opened, blister strips must be stored in the outer box.
Child Safety & Stability	The medicine must be kept strictly out of the sight and reach of children. Do not use the tablets after the expiry date shown on the package.
Disposal Instructions	Do not throw away any medicines via wastewater or household waste. Disposal of unused or expired product must be done according to the instructions provided by the pharmacist or local regulations to help protect the environment.

---

Regulatory documents define how this product must be stored by specifying mandatory temperature limits and requiring protection from moisture and light to maintain product integrity. They also establish strict packaging constraints by requiring storage in the original container. Final regulations mandate proper end-of-life handling by explicitly prohibiting disposal in household trash or wastewater.